Search

REGENXBIO Inc

Avatud

SektorTervishoid

8.9 10.56

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

7.73

Max

8.66

Põhinäitajad

By Trading Economics

Sissetulek

113M

23M

Müük

102M

108M

Aktsiakasum

0.43

Kasumimarginaal

21.023

Töötajad

371

EBITDA

112M

34M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+175.68% upside

Dividendid

By Acuity

Järgmine tulemuste avaldamine

5. nov 2026

Turustatistika

By TradingEconomics

Turukapital

128M

748M

Eelmine avamishind

-1.66

Eelmine sulgemishind

8.9

Uudiste sentiment

By Acuity

58%

42%

291 / 340 Pingereas Healthcare

REGENXBIO Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

24. aug 2026, 19:51 UTC

News
Social Media
Event

Regenxbio Inc shares are lower following the FDA's clinical hold on RGX-121 due to MRI findings, with Bank of America maintaining a $15 price target.

21. aug 2026, 19:26 UTC

Regenxbio Inc shares are declining today amid notable volatility, pulling back significantly from an earlier peak during the session. No specific news was identified.

20. aug 2026, 20:02 UTC

Regenxbio Inc. shares are lower as biotechnology stocks face pressure today, with no specific news identified to explain the decline.

19. aug 2026, 22:06 UTC

Regenxbio Inc shares are higher in after-market trading, continuing a positive trend since Wednesday's close and remaining above their 20-day moving average.

18. aug 2026, 19:46 UTC

Regenxbio Inc's shares are lower today amid rising Treasury yields and inflation concerns. The stock remains above its 20-day moving average.

17. aug 2026, 20:06 UTC

Regenxbio Inc shares are higher today, reflecting strong market performance. The stock remains near its one-month high and above its 20-day moving average.

14. aug 2026, 19:36 UTC

Regenxbio Inc shares are higher during Friday's session, advancing despite a reported decline in retail sales for July.

13. aug 2026, 21:31 UTC

Regenxbio Inc shares are lower in after-market hours, pulling back from an earlier session high. No specific news was identified to explain the decline.

12. aug 2026, 19:41 UTC

Regenxbio Inc shares are higher today amid positive market sentiment following a modest increase in the core Consumer Price Index.

11. aug 2026, 19:11 UTC

Biotechnology stocks are advancing today, contributing to Regenxbio Inc's higher price movement. The stock pulled back earlier but remains in positive territory overall.

10. aug 2026, 19:46 UTC

News

Regenxbio Inc shares are lower today after H.C. Wainwright cut its price target to $23.00, despite a strong Q2 earnings report.

7. aug 2026, 20:06 UTC

News

Barclays downgraded Regenxbio Inc to Equal-Weight from Overweight, maintaining a $12 price target. Shares are trading lower amid concerns about growth prospects.

6. aug 2026, 23:31 UTC

News

Regenxbio Inc shares are higher in after-market hours following key milestones in its Q2 2026 earnings call, including FDA alignment for RGX-202's development.

5. aug 2026, 19:26 UTC

Regenxbio Inc shares are higher during Wednesday's session, despite intraday volatility. Broader market sentiment is influenced by a recent decline in crude oil prices.

4. aug 2026, 19:56 UTC

Regenxbio Inc shares are higher, reflecting market strength amid a decline in crude oil prices that eased inflation concerns. No specific company news was identified.

31. juuli 2026, 19:36 UTC

Regenxbio Inc shares are lower, influenced by declines in the Biotechnology sector. The stock showed volatility, briefly rising earlier in the session.

30. juuli 2026, 19:29 UTC

Regenxbio Inc shares are higher during Thursday's session, continuing an upward trend since Wednesday. The stock remains below its 20-day moving average.

29. juuli 2026, 19:56 UTC

Macro Event

Regenxbio Inc is trading higher as the Federal Reserve maintains interest rates, reflecting heightened market sensitivity amid ongoing economic growth and geopolitical tensions.

28. juuli 2026, 18:16 UTC

Regenxbio Inc shares are lower, continuing a three-day decline amid broader market pressures, including losses in Asian markets like the Nikkei 225 Index.

27. juuli 2026, 19:36 UTC

Regenxbio Inc is trading higher during Monday's session, recovering from earlier declines. Broader market sentiment is influenced by a significant drop in oil prices.

24. juuli 2026, 20:07 UTC

Regenxbio Inc shares are lower today, continuing a decline since Thursday's close. The stock remains below its 20-day moving average, indicating market weakness.

22. juuli 2026, 18:26 UTC

Regenxbio Inc shares are lower amid geopolitical tensions and rising crude oil prices. Earlier in the session, shares briefly recovered but have since declined.

21. juuli 2026, 19:31 UTC

Regenxbio Inc is higher during Tuesday's session, tracking the broader market's gains amid positive sentiment from recent earnings reports. No specific company news was identified.

20. juuli 2026, 19:31 UTC

Event
News
Social Media

Regenxbio shares rise after positive long-term trial results for surabgene lomparvovec, showing sustained vision improvements in patients with retinal conditions.

Võrdlus sarnastega

Hinnamuutus

REGENXBIO Inc Prognoos

Hinnasiht

By TipRanks

175.68% tõus

12 kuu keskmine prognoos

Keskmine 22.22 USD  175.68%

Kõrge 42 USD

Madal 10 USD

Põhineb 9 Wall Streeti analüütiku instrumendi REGENXBIO Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

9 ratings

7

Osta

2

Hoia

0

Müü

Sentiment

By Acuity

291 / 340 Pingereas Tervishoid

Uudiste sentiment

Tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest REGENXBIO Inc

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
help-icon Live chat